AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 38778416 — intervention group
Group type: COMPARATOR
Intervention: Early progressive upright positioning (EPUP)
Number of subjects: 65
Study 38778549 — intervention group
Group type: EXPERIMENTAL
Intervention: Tofacitinib 5 or 10 mg b.i.d.
Number of subjects: 1157
Study 38778803 — intervention group
Group type: EXPERIMENTAL
Intervention: ECPR treatment
Number of subjects: 134
Study 38778803 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment
Number of subjects: 134
Study 38778807 — intervention group
Group type: EXPERIMENTAL
Intervention: Omega-3 PUFA supplementation and aerobic exercise training
Number of subjects: 0
Study 38778807 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 38779539 — intervention group
Group type: EXPERIMENTAL
Intervention: Hominis placental (HPP) extract
Number of subjects: 82
Study 38779539 — intervention group
Group type: COMPARATOR
Intervention: Physical therapy (PT)
Number of subjects: 82
Study 38779575 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-intensity robot-assisted gait training (RAGT) at progressively increasing intensity
Number of subjects: 24
Study 38779575 — intervention group
Group type: COMPARATOR
Intervention: Conventional robot-assisted gait training (RAGT)
Number of subjects: 24
Study 38779575 — intervention group
Group type: COMPARATOR
Intervention: Overground gait training (OGT)
Number of subjects: 24
Study 38779740 — intervention group
Group type: EXPERIMENTAL
Intervention: Defibrotide (25 mg/kg intravenously, divided into four daily doses over 14 days)
Number of subjects: 0
Study 38779740 — intervention group
Group type: COMPARATOR
Intervention: Standard of care only (control cohort)
Number of subjects: 0
Study 38779911 — intervention group
Group type: EXPERIMENTAL
Intervention: Targeted treatments based on molecular profiling (24 drugs available)
Number of subjects: 1167
Study 38780066 — intervention group
Group type: EXPERIMENTAL
Intervention: Restrictive RBC transfusion strategy
Number of subjects: 644
Study 38780185 — intervention group
Group type: EXPERIMENTAL
Intervention: App-based mental training (MT) for 3 months, daily 10-minute sessions
Number of subjects: 174
Study 38780185 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 174
Study 38780185 — intervention group
Group type: EXPERIMENTAL
Intervention: App-based mental training (MT)
Number of subjects: 174
Study 38780262 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefepime-taniborbactam
Number of subjects: 0
Study 38780262 — intervention group
Group type: COMPARATOR
Intervention: Meropenem
Number of subjects: 0
Study 38780386 — intervention group
Group type: EXPERIMENTAL
Intervention: Telemedicine-supported early discharge program
Number of subjects: 19
Study 38780434 — intervention group
Group type: EXPERIMENTAL
Intervention: ETDRS group
Number of subjects: 49
Study 38780434 — intervention group
Group type: COMPARATOR
Intervention: Landolt C group
Number of subjects: 49
Study 38780434 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 49
Study 38780446 — intervention group
Group type: EXPERIMENTAL
Intervention: Netarsudil
Number of subjects: 25
Study 38780499 — intervention group
Group type: EXPERIMENTAL
Intervention: Living kidney donation
Number of subjects: 924
Study 38780499 — intervention group
Group type: COMPARATOR
Intervention: Nondonors
Number of subjects: 924
Study 38780528 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual Reality Mindfulness
Number of subjects: 0
Study 38780528 — intervention group
Group type: EXPERIMENTAL
Intervention: Accelerated Transcranial Magnetic Stimulation Protocol 1
Number of subjects: 0
Study 38780528 — intervention group
Group type: EXPERIMENTAL
Intervention: Accelerated Transcranial Magnetic Stimulation Protocol 2
Number of subjects: 0
Study 38780536 — intervention group
Group type: EXPERIMENTAL
Intervention: High-Frequency Transcranial Magnetic Stimulation
Number of subjects: 0
Study 38780604 — intervention group
Group type: EXPERIMENTAL
Intervention: Family Check-Up (FCU) intervention
Number of subjects: 321
Study 38780814 — intervention group
Group type: EXPERIMENTAL
Intervention: Foot plantar massage
Number of subjects: 70
Study 38780927 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab (240 mg IV every 2 weeks for 5 cycles during IMRT, then 480 mg IV every 4 weeks for a total of 52 weeks)
Number of subjects: 51
Study 38780927 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab during IMRT reirradiation
Number of subjects: 51
Study 38780927 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab and IMRT reirradiation
Number of subjects: 51
Study 38780948 — intervention group
Group type: EXPERIMENTAL
Intervention: SZMN block group (n=26)
Number of subjects: 53
Study 38780948 — intervention group
Group type: COMPARATOR
Intervention: Control group (n=27)
Number of subjects: 53
Study 38780948 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 53
Study 38780953 — intervention group
Group type: EXPERIMENTAL
Intervention: OCTA metrics (Skeletonized Vessel Density and Perfusion Density) and Color Fundus Photography (CFP) images
Number of subjects: 122
Study 38780953 — intervention group
Group type: EXPERIMENTAL
Intervention: Microaneurysm turnover analysis
Number of subjects: 122
Study 38780959 — intervention group
Group type: EXPERIMENTAL
Intervention: Mandibular Advancement Device (MAD)
Number of subjects: 50
Study 38780959 — intervention group
Group type: COMPARATOR
Intervention: Combined Airway and Positional Therapy (CAPT)
Number of subjects: 50
Study 38780960 — intervention group
Group type: EXPERIMENTAL
Intervention: Multilevel intervention (6-month patient-level lay health worker structured ACP education + clinician-level intervention with 3-hour ACP training and structured electronic health record documentation template)
Number of subjects: 402
Study 38780960 — intervention group
Group type: EXPERIMENTAL
Intervention: Multilevel intervention
Number of subjects: 402
Study 38780960 — intervention group
Group type: COMPARATOR
Intervention: Control group (clinician-level intervention alone)
Number of subjects: 402
Study 38780998 — intervention group
Group type: EXPERIMENTAL
Intervention: AR-based educational program
Number of subjects: 28
Study 38781006 — intervention group
Group type: EXPERIMENTAL
Intervention: iCPR CDS-based intervention for registered nurses (RNs)
Number of subjects: 43
Study 38781010 — intervention group
Group type: EXPERIMENTAL
Intervention: Suicide Prevention by Peers Offering Recovery Tactics (SUPPORT)
Number of subjects: 11
Study 38781010 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer specialist training
Number of subjects: 11
Study 38781013 — intervention group
Group type: EXPERIMENTAL
Intervention: Lanthanum Carbonate
Number of subjects: 0
Study 38781013 — intervention group
Group type: COMPARATOR
Intervention: Control (placebo or standard treatment)
Number of subjects: 0
Study 38781043 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraoperative frozen section (FS) diagnosis
Number of subjects: 935
Study 38781168 — intervention group
Group type: EXPERIMENTAL
Intervention: Multimedia educational videos with evidence-informed design principles
Number of subjects: 0
Study 38781168 — intervention group
Group type: EXPERIMENTAL
Intervention: Multimedia educational videos without evidence-informed design principles
Number of subjects: 0
Study 38781168 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 0
Study 38781315 — intervention group
Group type: EXPERIMENTAL
Intervention: Acalabrutinib, venetoclax, and rituximab (AVR)
Number of subjects: 21
Study 38781350 — intervention group
Group type: EXPERIMENTAL
Intervention: Computerized history taking software (CHT)
Number of subjects: 1000
Study 38781350 — intervention group
Group type: COMPARATOR
Intervention: Physician-acquired medical history (EHR)
Number of subjects: 1000
Study 38781350 — intervention group
Group type: EXPERIMENTAL
Intervention: Agreement between CHT and EHR
Number of subjects: 1000
Study 38781428 — intervention group
Group type: EXPERIMENTAL
Intervention: Secondary mitral regurgitation (MR) with MR volume ≥ 24 mL
Number of subjects: 241
Study 38781428 — intervention group
Group type: EXPERIMENTAL
Intervention: Secondary mitral regurgitation (MR) with MR fraction ≥ 30%
Number of subjects: 241
Study 38781428 — intervention group
Group type: EXPERIMENTAL
Intervention: Increasing RV ejection fraction (RVEF)
Number of subjects: 241
Study 38781428 — intervention group
Group type: COMPARATOR
Intervention: RV dysfunction (RVEF < 45%)
Number of subjects: 241
Study 38781564 — intervention group
Group type: EXPERIMENTAL
Intervention: CAR-37 T cells
Number of subjects: 5
Study 38781591 — intervention group
Group type: EXPERIMENTAL
Intervention: Active treatment (maintained on antihypertensive therapy with a goal BP below 140/90 mm Hg)
Number of subjects: 2284
Study 38781593 — intervention group
Group type: EXPERIMENTAL
Intervention: 24-hour mifepristone-to-misoprostol interval
Number of subjects: 80
Study 38781593 — intervention group
Group type: COMPARATOR
Intervention: 12-hour mifepristone-to-misoprostol interval
Number of subjects: 80
Study 38781634 — intervention group
Group type: EXPERIMENTAL
Intervention: Contraceptive switching or discontinuation
Number of subjects: 4289
Study 38781634 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuing with baseline method
Number of subjects: 4289
Study 38781634 — intervention group
Group type: EXPERIMENTAL
Intervention: Method change (switching or discontinuing)
Number of subjects: 4289
Study 38781634 — intervention group
Group type: EXPERIMENTAL
Intervention: Both switching and discontinuation
Number of subjects: 4289
Study 38781634 — intervention group
Group type: EXPERIMENTAL
Intervention: Discontinuation
Number of subjects: 4289
Study 38781634 — intervention group
Group type: EXPERIMENTAL
Intervention: Subsequent method after discontinuation
Number of subjects: 4289
Study 38781664 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorthalidone/amiloride 25/5 mg
Number of subjects: 0
Study 38781664 — intervention group
Group type: COMPARATOR
Intervention: Amlodipine 10 mg
Number of subjects: 0
Study 38781965 — intervention group
Group type: EXPERIMENTAL
Intervention: Immune checkpoint inhibitors (ICIs) treatment, with or without chemotherapy, for front-/subsequent-line therapy.
Number of subjects: 3288
Study 38781965 — intervention group
Group type: EXPERIMENTAL
Intervention: DT10-predicted-DCB patients
Number of subjects: 3288
Study 38781965 — intervention group
Group type: EXPERIMENTAL
Intervention: DT10-predicted-NDB (non-durable benefit) group
Number of subjects: 3288
Study 38782015 — intervention group
Group type: EXPERIMENTAL
Intervention: Arimoclomol citrate 1200 mg/day (400 mg three times per day)
Number of subjects: 239
Study 38782015 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 239
Study 38782015 — intervention group
Group type: EXPERIMENTAL
Intervention: Arimoclomol
Number of subjects: 239
Study 38782091 — intervention group
Group type: EXPERIMENTAL
Intervention: Hands-on technique at the time of delivery
Number of subjects: 0
Study 38782091 — intervention group
Group type: COMPARATOR
Intervention: Hands-off technique at the time of delivery
Number of subjects: 0
Study 38782118 — intervention group
Group type: EXPERIMENTAL
Intervention: Multi-region sampling approach
Number of subjects: 123
Study 38782232 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness and motivational interviewing-oriented physical-psychological integrated intervention (n=36)
Number of subjects: 72
Study 38782232 — intervention group
Group type: COMPARATOR
Intervention: Control group (didactic education on lifestyle discussions and general health suggestions) (n=36)
Number of subjects: 72
Study 38782542 — intervention group
Group type: EXPERIMENTAL
Intervention: EVX-01 (personalized peptide-based neoantigen vaccine)
Number of subjects: 12
Study 38782549 — intervention group
Group type: EXPERIMENTAL
Intervention: Filgotinib 100 mg
Number of subjects: 3691
Study 38782549 — intervention group
Group type: EXPERIMENTAL
Intervention: Filgotinib 200 mg
Number of subjects: 3691
Study 38782609 — intervention group
Group type: EXPERIMENTAL
Intervention: Crushed venetoclax tablets
Number of subjects: 15
Study 38782609 — intervention group
Group type: EXPERIMENTAL
Intervention: Ground venetoclax tablets
Number of subjects: 15
Study 38782609 — intervention group
Group type: COMPARATOR
Intervention: Intact venetoclax tablets
Number of subjects: 15
Study 38782726 — intervention group
Group type: EXPERIMENTAL
Intervention: Volenrelaxin (intravenous or subcutaneous)
Number of subjects: 133
Study 38782726 — intervention group
Group type: EXPERIMENTAL
Intervention: Volenrelaxin (subcutaneous once weekly for 5 weeks)
Number of subjects: 133
Study 38782726 — intervention group
Group type: EXPERIMENTAL
Intervention: Volenrelaxin
Number of subjects: 133
Study 38782726 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 133
Study 38782968 — intervention group
Group type: EXPERIMENTAL
Intervention: Shear wave elastography (SWE)
Number of subjects: 90
Study 38782968 — intervention group
Group type: COMPARATOR
Intervention: Qualitative B-mode cranial ultrasound (cUS)
Number of subjects: 90
Study 38783176 — intervention group
Group type: EXPERIMENTAL
Intervention: MAF capsules
Number of subjects: 204
Study 38783176 — intervention group
Group type: EXPERIMENTAL
Intervention: M capsules
Number of subjects: 204
Study 38783176 — intervention group
Group type: COMPARATOR
Intervention: Standard of care (SOC) only
Number of subjects: 204
Study 38783205 — intervention group
Group type: EXPERIMENTAL
Intervention: Multimodal treatment program over 24 weeks
Number of subjects: 915
Study 38783238 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab (anti-PD-1) maintenance therapy discontinued early after achieving CR/PR
Number of subjects: 80
Study 38783268 — intervention group
Group type: EXPERIMENTAL
Intervention: Early pathophysiology-driven airway pressure release ventilation (APRV)
Number of subjects: 840
Study 38783268 — intervention group
Group type: COMPARATOR
Intervention: Low tidal volume ventilation (LTV)
Number of subjects: 840
Study 38783268 — intervention group
Group type: EXPERIMENTAL
Intervention: APRV
Number of subjects: 840
Study 38783268 — intervention group
Group type: COMPARATOR
Intervention: LTV
Number of subjects: 840
Study 38783296 — intervention group
Group type: EXPERIMENTAL
Intervention: Smartphone arm (e-mail transmission of photographs)
Number of subjects: 250
Study 38783296 — intervention group
Group type: COMPARATOR
Intervention: Usual care arm (standard referral practice)
Number of subjects: 250
Study 38783301 — intervention group
Group type: EXPERIMENTAL
Intervention: For-profit healthcare facilities
Number of subjects: 8941
Study 38783301 — intervention group
Group type: EXPERIMENTAL
Intervention: Micropolitan location
Number of subjects: 8941
Study 38783312 — intervention group
Group type: EXPERIMENTAL
Intervention: CeraTip™ depigmentation
Number of subjects: 8
Study 38783312 — intervention group
Group type: COMPARATOR
Intervention: Scalpel depigmentation
Number of subjects: 8
Study 38783322 — intervention group
Group type: EXPERIMENTAL
Intervention: Group-based psychoeducation (6 sessions of 2 hours each)
Number of subjects: 200
Study 38783322 — intervention group
Group type: COMPARATOR
Intervention: Waiting list (control group)
Number of subjects: 200
Study 38783322 — intervention group
Group type: EXPERIMENTAL
Intervention: Group-based psychoeducation
Number of subjects: 200
Study 38783367 — intervention group
Group type: EXPERIMENTAL
Intervention: Dyspnea-VAS (visual analog scale)
Number of subjects: 310
Study 38783367 — intervention group
Group type: EXPERIMENTAL
Intervention: Intubation
Number of subjects: 310
Study 38783367 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate dyspnea (dyspnea-VAS 40-64 mm)
Number of subjects: 310
Study 38783367 — intervention group
Group type: EXPERIMENTAL
Intervention: Severe dyspnea (dyspnea-VAS ≥ 65 mm)
Number of subjects: 310
Study 38783367 — intervention group
Group type: EXPERIMENTAL
Intervention: Systolic arterial pressure
Number of subjects: 310
Study 38783367 — intervention group
Group type: EXPERIMENTAL
Intervention: Heart rate
Number of subjects: 310
Study 38783367 — intervention group
Group type: EXPERIMENTAL
Intervention: 90-day mortality
Number of subjects: 310
Study 38783427 — intervention group
Group type: EXPERIMENTAL
Intervention: Propolis
Number of subjects: 22
Study 38783427 — intervention group
Group type: COMPARATOR
Intervention: Gluma
Number of subjects: 22
Study 38783836 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-Based Training for Cognitive Behavioural Therapy (CBT4CBT)
Number of subjects: 0
Study 38783836 — intervention group
Group type: COMPARATOR
Intervention: Standard care (TAU)
Number of subjects: 0
Study 38783863 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulmonary rehabilitation program
Number of subjects: 16
Study 38783863 — intervention group
Group type: COMPARATOR
Intervention: Baseline measurement
Number of subjects: 16
Study 38783987 — intervention group
Group type: EXPERIMENTAL
Intervention: Emicizumab
Number of subjects: 504
Study 38784165 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobile app-based self-guided psychological intervention (Nałogometr 2.0) incorporating mindfulness techniques and Cognitive Behavioral Therapy (CBT) principles over three months.
Number of subjects: 0
Study 38784165 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobile app-based self-guided psychological intervention (Nałogometr 2.0)
Number of subjects: 0
Study 38784572 — intervention group
Group type: EXPERIMENTAL
Intervention: COVID-19 lockdown measures
Number of subjects: 48
Study 38784617 — intervention group
Group type: EXPERIMENTAL
Intervention: LIFEwithIBD intervention (Acceptance and Commitment Therapy and compassion-based intervention)
Number of subjects: 355
Study 38784617 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 355
Study 38784617 — intervention group
Group type: EXPERIMENTAL
Intervention: LIFEwithIBD intervention
Number of subjects: 355
Study 38784791 — intervention group
Group type: EXPERIMENTAL
Intervention: Peginterferon beta-1a
Number of subjects: 0
Study 38784916 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcranial pulse stimulation (TPS)
Number of subjects: 30
Study 38784916 — intervention group
Group type: COMPARATOR
Intervention: Sham TPS
Number of subjects: 30
Study 38784965 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioural change techniques delivered alongside an exercise programme
Number of subjects: 20
Study 38784965 — intervention group
Group type: COMPARATOR
Intervention: Usual care (multidisciplinary education, supervised exercise class, prescribed home exercise program)
Number of subjects: 20
Study 38785084 — intervention group
Group type: EXPERIMENTAL
Intervention: FFR-guided strategy
Number of subjects: 1163
Study 38785084 — intervention group
Group type: COMPARATOR
Intervention: Angiography-guided strategy
Number of subjects: 1163
Study 38785209 — intervention group
Group type: EXPERIMENTAL
Intervention: Semaglutide
Number of subjects: 3533
Study 38785259 — intervention group
Group type: EXPERIMENTAL
Intervention: PSMA-PET
Number of subjects: 50
Study 38785259 — intervention group
Group type: COMPARATOR
Intervention: mpMRI
Number of subjects: 50
Study 38785314 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced hydration (20 mL/kg body weight, one-third given via bolus and remainder over 8 hours)
Number of subjects: 488
Study 38785314 — intervention group
Group type: COMPARATOR
Intervention: Standard hydration (60 mL/h for 8 hours, followed by maintenance infusion of 40-80 mL/h for the subsequent 64 hours)
Number of subjects: 488
Study 38785314 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced hydration
Number of subjects: 488
Study 38785314 — intervention group
Group type: COMPARATOR
Intervention: Standard hydration
Number of subjects: 488
Study 38785405 — intervention group
Group type: EXPERIMENTAL
Intervention: Dupilumab
Number of subjects: 311
Study 38785405 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 311
Study 38785484 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrahypofractionated (UHF) MRI-guided radiotherapy on a 1.5 T MR-Linac with a dose of 42.7 Gy in seven fractions
Number of subjects: 23
Study 38785484 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrahypofractionated (UHF) MRI-guided radiotherapy on a 1.5 T MR-Linac
Number of subjects: 23
Study 38786455 — intervention group
Group type: EXPERIMENTAL
Intervention: Health education intervention (HEI)
Number of subjects: 0
Study 38786455 — intervention group
Group type: COMPARATOR
Intervention: Comparator group (control)
Number of subjects: 0
Study 38786579 — intervention group
Group type: EXPERIMENTAL
Intervention: Orsiro biodegradable polymer SES
Number of subjects: 328
Study 38786579 — intervention group
Group type: COMPARATOR
Intervention: Coroflex ISAR polymer-free sirolimus-eluting stent
Number of subjects: 328
Study 38787303 — intervention group
Group type: EXPERIMENTAL
Intervention: Auditory processing measures in the binaural domain
Number of subjects: 274
Study 38787303 — intervention group
Group type: COMPARATOR
Intervention: Peripheral hearing
Number of subjects: 274
Study 38787436 — intervention group
Group type: EXPERIMENTAL
Intervention: Time in tight range (TITR: 3.9-7.8 mmol/l)
Number of subjects: 808
Study 38787436 — intervention group
Group type: EXPERIMENTAL
Intervention: Time in range (TIR: 3.9-10.0 mmol/l)
Number of subjects: 808
Study 38787436 — intervention group
Group type: EXPERIMENTAL
Intervention: Increasing TITR/TIR quartiles
Number of subjects: 808
Study 38787559 — intervention group
Group type: EXPERIMENTAL
Intervention: Neuromuscular exercise and pain neuroscience education
Number of subjects: 69
Study 38787559 — intervention group
Group type: COMPARATOR
Intervention: Pain neuroscience education alone
Number of subjects: 69
Study 38787559 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 69
Study 38787562 — intervention group
Group type: EXPERIMENTAL
Intervention: Remote, pushed digital assessments and engagement (monthly text messaging about mental health, mental health assessments, and linkages to care)
Number of subjects: 1275
Study 38787562 — intervention group
Group type: COMPARATOR
Intervention: Usual care (open access to a web-based mental health platform)
Number of subjects: 1275
Study 38787613 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness Ecological Momentary Intervention (EMI)
Number of subjects: 110
Study 38787613 — intervention group
Group type: COMPARATOR
Intervention: Self-monitoring app
Number of subjects: 110
Study 38787613 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness EMI
Number of subjects: 110
Study 38787930 — intervention group
Group type: EXPERIMENTAL
Intervention: Endovascular thrombectomy (EVT)
Number of subjects: 734
Study 38787930 — intervention group
Group type: COMPARATOR
Intervention: Intravenous thrombolysis (IVT)
Number of subjects: 734
Study 38788174 — intervention group
Group type: EXPERIMENTAL
Intervention: CT041 (CAR-modified T-cell therapy targeting claudin18.2)
Number of subjects: 24
Study 38788175 — intervention group
Group type: EXPERIMENTAL
Intervention: Tranexamic acid (TXA) treatment in good-grade aSAH (N = 232)
Number of subjects: 812